-
Je něco špatně v tomto záznamu ?
Ion mobility-high resolution mass spectrometry in doping control analysis. Part II: Comparison of acquisition modes with and without ion mobility
K. Plachká, J. Pezzatti, A. Musenga, R. Nicoli, T. Kuuranne, S. Rudaz, L. Nováková, D. Guillarme
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- doping ve sportu * MeSH
- glukokortikoidy MeSH
- iontová mobilní spektrometrie * MeSH
- narkotika MeSH
- steroidy MeSH
- tandemová hmotnostní spektrometrie MeSH
- Publikační typ
- časopisecké články MeSH
In the second part of this study, a systematic comparison was made between two ion fragmentation acquisition modes, namely data-independent acquisition (DIA) and DIA with ion mobility spectrometry (IMS) technology. These two approaches were applied to the analysis of 192 doping agents in urine. Group I included 102 compounds such as stimulants, diuretics, narcotics, and β2-agonists, while Group II contained 90 compounds included steroids, glucocorticoids, and hormone and metabolic modulators. Important method parameters were examined and compared, including the fragmentation, sensitivity, and assignment capability with the minimum occurrence of false positive hits. The results differed between Group I and II in number of detected fragments when exploring the MS/MS spectra. In Group I only 13%, while in the Group II 64% of the substances had a higher number of fragments in DIA-IMS mode vs. DIA. In terms of sensitivity, the performance of the two modes with and without activated IMS dimension was identical for about 50% of the doping agents. The sensitivity was higher without IMS, i.e. in simple DIA mode, for 20-40% of remaining doping agents. Despite this sensitivity reduction with IMS, 82% of compounds from both Groups met the minimum required performance level (MRPL) criteria of the World Anti-Doping Agency (WADA) when the DIA-IMS mode was applied. Automated data processing is important in routine doping analysis. Therefore, processing methods were optimized and evaluated for the prevalence of false peak assignments by analysing the target substances at different concentrations in urine samples. Overall, a significantly higher number of misidentified compounds was observed in Group II, with an almost 2-fold higher number of misidentifications in DIA compared to DIA-IMS. This result highlights the benefit of the IMS dimension to reduce the rate of false positive in screening analysis. The optimized UHPLC-IM-HRMS method was finally applied to the analysis of urine samples from administration studies including nine doping agents from both Groups. However, to limit the number of interferences from the biological matrix, an emphasis is needed on the adequate settings of the data processing method.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025078
- 003
- CZ-PrNML
- 005
- 20211026134141.0
- 007
- ta
- 008
- 211013s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.aca.2021.338739 $2 doi
- 035 __
- $a (PubMed)34330438
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Plachká, Kateřina $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05, Hradec Králové, Czech Republic
- 245 10
- $a Ion mobility-high resolution mass spectrometry in doping control analysis. Part II: Comparison of acquisition modes with and without ion mobility / $c K. Plachká, J. Pezzatti, A. Musenga, R. Nicoli, T. Kuuranne, S. Rudaz, L. Nováková, D. Guillarme
- 520 9_
- $a In the second part of this study, a systematic comparison was made between two ion fragmentation acquisition modes, namely data-independent acquisition (DIA) and DIA with ion mobility spectrometry (IMS) technology. These two approaches were applied to the analysis of 192 doping agents in urine. Group I included 102 compounds such as stimulants, diuretics, narcotics, and β2-agonists, while Group II contained 90 compounds included steroids, glucocorticoids, and hormone and metabolic modulators. Important method parameters were examined and compared, including the fragmentation, sensitivity, and assignment capability with the minimum occurrence of false positive hits. The results differed between Group I and II in number of detected fragments when exploring the MS/MS spectra. In Group I only 13%, while in the Group II 64% of the substances had a higher number of fragments in DIA-IMS mode vs. DIA. In terms of sensitivity, the performance of the two modes with and without activated IMS dimension was identical for about 50% of the doping agents. The sensitivity was higher without IMS, i.e. in simple DIA mode, for 20-40% of remaining doping agents. Despite this sensitivity reduction with IMS, 82% of compounds from both Groups met the minimum required performance level (MRPL) criteria of the World Anti-Doping Agency (WADA) when the DIA-IMS mode was applied. Automated data processing is important in routine doping analysis. Therefore, processing methods were optimized and evaluated for the prevalence of false peak assignments by analysing the target substances at different concentrations in urine samples. Overall, a significantly higher number of misidentified compounds was observed in Group II, with an almost 2-fold higher number of misidentifications in DIA compared to DIA-IMS. This result highlights the benefit of the IMS dimension to reduce the rate of false positive in screening analysis. The optimized UHPLC-IM-HRMS method was finally applied to the analysis of urine samples from administration studies including nine doping agents from both Groups. However, to limit the number of interferences from the biological matrix, an emphasis is needed on the adequate settings of the data processing method.
- 650 12
- $a doping ve sportu $7 D004300
- 650 _2
- $a glukokortikoidy $7 D005938
- 650 12
- $a iontová mobilní spektrometrie $7 D000075663
- 650 _2
- $a narkotika $7 D009294
- 650 _2
- $a steroidy $7 D013256
- 650 _2
- $a tandemová hmotnostní spektrometrie $7 D053719
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pezzatti, Julian $u School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, CMU-Rue Michel Servet 1, 1211, Geneva 4, Switzerland
- 700 1_
- $a Musenga, Alessandro $u Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Switzerland
- 700 1_
- $a Nicoli, Raul $u Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Switzerland
- 700 1_
- $a Kuuranne, Tiia $u Swiss Laboratory for Doping Analyses, University Center of Legal Medicine Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Switzerland
- 700 1_
- $a Rudaz, Serge $u School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, CMU-Rue Michel Servet 1, 1211, Geneva 4, Switzerland
- 700 1_
- $a Nováková, Lucie $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05, Hradec Králové, Czech Republic
- 700 1_
- $a Guillarme, Davy $u School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211, Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, CMU-Rue Michel Servet 1, 1211, Geneva 4, Switzerland. Electronic address: Davy.Guillarme@unige.ch
- 773 0_
- $w MED00000332 $t Analytica chimica acta $x 1873-4324 $g Roč. 1175, č. - (2021), s. 338739
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34330438 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134147 $b ABA008
- 999 __
- $a ok $b bmc $g 1714228 $s 1145585
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 1175 $c - $d 338739 $e 20210607 $i 1873-4324 $m Analytica chimica acta $n Anal. chim. acta (Print) $x MED00000332
- LZP __
- $a Pubmed-20211013